Restenosis News and Research

RSS

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.

Spectranetics seeks FDA clearance for treating in-stent restenosis in the legs

Spectranetics Corporation today announced that it has filed a 510(k) application with the Food and Drug Administration seeking clearance for the treatment of in-stent restenosis (ISR) in the legs with its commercially available peripheral atherectomy products. ISR is caused by the re-growth of tissue within the stent, known as neointimal hyperplasia, which can lead to blockages in the affected leg artery.

29 Sep 2009

Pre-clinical data demonstrates advantages of Combo Stent

OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.

24 Sep 2009

Genous Bio-engineered R stent for STEMI implantation exhibits safety

OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).

23 Sep 2009

Drug-eluting stents effective for diabetic patients

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

Pervasis Therapeutics raises funds to support clinical development programs

Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.

17 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

Study reveals feasibility of OrbusNeich's Genous stent in patients needing undeferrable non-cardiac surgery

OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

14 Sep 2009

U.S patent for Tryton Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that a U.S. patent has been awarded for the company’s Tryton Side Branch Stent™ System.

10 Sep 2009

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

AVI BioPharma, Inc., a developer of RNA-based drugs, today announced that Hong Moulton, Ph.D., Director of Discovery Research, will give oral presentations highlighting improved analogues of AVI's phosphorodiamidate morpholino oligomer (PMO) chemistry at two upcoming scientific meetings.

28 Aug 2009

Drug-eluting stents more effective than bare-metal stents in heart attack patients

NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.

26 May 2009

Cytomegalovirus may cause high blood pressure

A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading risk factor for heart disease, stroke and kidney disease.

15 May 2009

Results from study comparing safety and efficacy of drug-eluting stents and bare-metal stents

The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.

6 May 2009

Drug-eluting stents found to be safer and superior to bare metal stents

Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.

29 Mar 2009

Saving limbs with drug-eluting stents

Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation.

11 Mar 2009

New procedure for eliminating reblockage of arteries

An easily implementable technique to avoid reblockage of arteries that have been cleared through angioplasty and stent insertion has been developed by researchers led by Prof. Boris Rubinsky of the Hebrew University of Jerusalem.

10 Mar 2009

Invatec launches drug-eluting balloon to treat atherosclerosis below the knee

Invatec, a comprehensive innovator of interventional products, today announced the European launch of a new peripheral balloon, the IN.PACT Amphirion paclitaxel-eluting PTA balloon catheter.

15 Jan 2009

Cell-coated stent as effective as drug-coated ones

A stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents in keeping arteries open in coronary heart disease patients, according to two research studies presented at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008